Your browser doesn't support javascript.
loading
Characterization of immune response against monkeypox virus in cohorts of infected patients, historic and newly vaccinated subjects.
Sammartino, Josè Camilla; Cassaniti, Irene; Ferrari, Alessandro; Piralla, Antonio; Bergami, Federica; Arena, Francesca Adua; Paolucci, Stefania; Rovida, Francesca; Lilleri, Daniele; Percivalle, Elena; Baldanti, Fausto.
Afiliação
  • Sammartino JC; Department of Clinical, Surgical, Diagnostics and Paediatric Sciences, University of Pavia, Pavia, Italy.
  • Cassaniti I; Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Ferrari A; Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Piralla A; Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Bergami F; Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Arena FA; Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Paolucci S; Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Rovida F; Department of Clinical, Surgical, Diagnostics and Paediatric Sciences, University of Pavia, Pavia, Italy.
  • Lilleri D; Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Percivalle E; Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Baldanti F; Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
J Med Virol ; 95(5): e28778, 2023 05.
Article em En | MEDLINE | ID: mdl-37212258
ABSTRACT
Monkeypox virus (MPXV) is a zoonotic disease endemic in the rainforest countries of Central and West Africa. Understanding the immune response in zoonosis is fundamental to prevent and contrast viral spreading. MPXV is a close relative of Variola (smallpox) virus and vaccination with vaccinia virus gives approximatively 85% of protection against MPXV. With the emergence of the recent MPXV outbreak, JYNNEOS vaccine has been proposed to individuals at high-risk of exposure. Comparative data on MPXV immune response in vaccinated or infected subjects are still limited. Here we set-up an immunofluorescence method for the evaluation of humoral response elicited by natural infection and healthy vaccinated subjects, including historically smallpox-vaccinated individuals and newly vaccinated subjects. Neutralization assay was also included, and in vaccinated subjects, cell-mediated response was evaluated. We observed that the natural infection produces a strong immune response that can control the disease. In naïve subjects, a second dose boosts the serological response to levels similar to those of the MPXV patients. Last, smallpox-vaccinated controls retain a degree of protection, even after years from vaccination, most visible in the t-cellular response.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Varíola / Mpox Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Varíola / Mpox Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article